Patient characteristics at diagnosis, overall and by treatment received in patients with incident stage IIIB–IV NSCLC
| All (N=2119) n (%) | Untreated (n=1471) n (%) | SACT treated (n=648) n (%) | |
| Age at diagnosis, years | |||
| <65 | 541 (25.5) | 249 (16.9) | 292 (45.1) |
| 65–74 | 671 (31.7) | 428 (29.1) | 243 (37.5) |
| ≥75 | 907 (42.8) | 794 (54.0) | 113 (17.4) |
| Diagnosis year | |||
| 2007–2012 | 1181 (55.7) | 843 (57.3) | 338 (52.2) |
| 2013–2017 | 938 (44.3) | 628 (42.7) | 310 (47.8) |
| Sex | |||
| Male | 1106 (52.2) | 755 (51.3) | 351 (54.2) |
| Female | 1013 (47.8) | 716 (48.7) | 297 (45.8) |
| BMI | |||
| <18.5 (underweight) | 37 (1.7) | 5 (0.3) | 32 (4.9) |
| 18.5–24.9 (healthy weight) | 299 (14.1) | 38 (2.6) | 261 (40.3) |
| 25–29.9 (overweight) | 248 (11.7) | 29 (2.0) | 219 (33.8) |
| ≥30 (obese) | 118 (5.6) | 12 (0.8) | 106 (16.4) |
| Missing/unknown | 1417 (66.9) | 1387 (94.3) | 30 (4.6) |
| ECOG PS | |||
| 0 | 145 (6.8) | 44 (3.0) | 101 (15.6) |
| 1 | 517 (24.4) | 231 (15.7) | 286 (44.1) |
| 2 | 414 (19.5) | 256 (17.4) | 158 (24.4) |
| 3 | 564 (26.6) | 518 (35.2) | 46 (7.1) |
| 4 | 284 (13.4) | 278 (18.9) | 6 (0.9) |
| Missing/unknown | 195 (9.2) | 144 (9.8) | 51 (7.9) |
| Pathology | |||
| NSQ | 666 (31.4) | 366 (24.9) | 300 (46.3) |
| SQ | 396 (18.7) | 216 (14.7) | 180 (27.8) |
| Other | 49 (2.3) | 20 (1.3) | 29 (4.5) |
| NOS NSCLC | 315 (14.9) | 201 (13.7) | 114 (17.6) |
| Clinically diagnosed* | 693 (32.7) | 668 (45.4) | 25 (3.8) |
| Stage | |||
| IIIB | 337 (15.9) | 198 (13.5) | 139 (21.4) |
| IV | 1782 (84.1) | 1273 (86.5) | 509 (78.6) |
*No pathological confirmation. A total of 25 patients were recorded as receiving treatment following clinical diagnosis; however, further investigations confirmed that all these patients had pathologically confirmed NSCLC.
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; NSQ, non-squamous; PS, performance status; ref, reference; SACT, systemic anticancer therapy; SQ, squamous.